Recent 8-K filings for OTLK
Highest-materiality recent filing
FDA grants Outlook Therapeutics appeal; BLA resubmission planned for June 2026
- FDA concluded substantial evidence of effectiveness for LYTENAVA (bevacizumab-vikg) for nAMD after FDR appeal.
- Company will resubmit BLA as Class 1 in June 2026; PDUFA decision expected within 60 days.
-
FDA grants Outlook Therapeutics appeal; BLA resubmission planned for June 2026
FDA concluded substantial evidence of effectiveness for LYTENAVA (bevacizumab-vikg) for nAMD after FDR appeal.
-
Outlook Therapeutics Q2 FY2026 net loss narrows to $4.5M; FDA decision on ONS-5010 expected May 2026
Net loss of $4.5M ($0.05/sh) vs $46.4M ($1.50/sh) YoY; adjusted net loss $14.1M ($0.16/sh).
-
Outlook Therapeutics enters new $100M ATM with H.C. Wainwright; cash at $7.7M
Entered into $100M at-the-market offering agreement with H.C. Wainwright & Co. as sales agent.
-
Outlook Therapeutics raises ~$5M in registered direct offering and private placement at $0.31/unit
Offering of 16,129,033 shares of common stock and accompanying Common Warrants at $0.31 per unit.
-
Completed Federal Dispute Resolution meeting with FDA Office of New Drugs to appeal Dec 30, 2025 Complete Response Letter for ONS-5010 BLA.
-
Outlook Therapeutics FDA accepts FDRR for ONS-5010; meeting set for April 2026
FDA accepted Formal Dispute Resolution Request for ONS-5010/LYTENAVA (bevacizumab) for wet AMD.
-
Outlook Therapeutics closes $5.0M offering of common stock and warrants
20M shares + 20M warrants sold at $0.25/unit; gross proceeds ~$5.0M, net ~$4.0M.
-
Issued $18.36M unsecured note (net $17M after OID) to Atlas Sciences; proceeds used to repay $17M of $33.1M Avondale Note.
-
Director Julia Haller resigns from Outlook Therapeutics board, effective March 11, 2026
Dr. Julia Haller resigned as Class II director, also serving on Nominating and Corporate Governance Committee.
-
Yezan Haddadin, Faisal G. Sukhtian, Kurt J. Hilzinger elected as Class I directors with votes for >12M each.
-
Outlook Therapeutics updates on Type A meeting with FDA for ONS-5010; no definitive resolution
Type A meeting held with FDA to discuss December 30, 2025 Complete Response Letter for ONS-5010 BLA.
-
Outlook Therapeutics receives Nasdaq minimum bid price deficiency notice; 180-day cure period
Received Nasdaq letter on Feb 18, 2026, for closing bid price below $1.00 for 30 consecutive business days.
-
Outlook Therapeutics Q1 FY2026 net loss $23.1M; unit sales of LYTENAVA double in Europe
Net loss of $23.1M ($0.38/share) vs net income of $17.4M ($0.72/share) in prior-year quarter.
-
Outlook Therapeutics requests Type A FDA meeting after CRL for wet AMD drug ONS-5010
CRL dated Dec 30, 2025 cited lack of substantial evidence; company believes it contradicts alignment from Sept 2025 meeting.
-
FDA issues Complete Response Letter for Outlook Therapeutics' ONS-5010 BLA for wet AMD
FDA CRL states additional mechanistic/natural history data does not alter prior conclusion; confirmatory efficacy evidence needed but not defined.
-
Outlook Therapeutics FY2025 net loss $62.4M; $1.4M revenue from LYTENAVA launch in Europe
Net loss $62.4M ($1.79/share) vs $75.4M ($4.06/share) prior year; revenue $1.4M from initial EU sales.
-
FDA accepts Outlook Therapeutics' BLA resubmission for ONS-5010; PDUFA date Dec 31, 2025
FDA acknowledged receipt of BLA resubmission for ONS-5010 (bevacizumab-vikg) and assigned Class 1 review.
-
Outlook Therapeutics resubmits BLA for ONS-5010 (wet AMD) to FDA after Sept 2025 Type A meeting
Resubmitted BLA on Nov 3, 2025 for ONS-5010 (LYTENAVA) to treat wet AMD.
-
Outlook Therapeutics completes FDA Type A meeting for ONS-5010 BLA; plans resubmission in 2025
Type A meeting with FDA discussed August 27, 2025 CRL for ONS-5010 BLA (bevacizumab for wet AMD).
-
Chief Commercial Officer Jeff Evanson departs Outlook Therapeutics effective immediately
Jeff Evanson stepped down as Chief Commercial Officer on September 5, 2025.
-
CRL cites lack of substantial evidence of effectiveness; ONS-5010 did not meet primary endpoint in NORSE EIGHT trial.
-
Outlook Therapeutics reports first LYTENAVA sales, $20.2M net loss for Q3 FY2025
First commercial sales of LYTENAVA (bevacizumab gamma) in Germany and UK; $1.5M revenue recognized.
-
Outlook Therapeutics appoints Robert C. Jahr as President and CEO, replacing interim CEO
Robert C. Jahr appointed President & CEO effective July 1, 2025; replaces interim CEO Lawrence Kenyon, who remains CFO and board member.
-
Outlook Therapeutics launches LYTENAVA (bevacizumab gamma) in Germany and UK for wet AMD
Commercial launch of LYTENAVA (bevacizumab gamma) in Germany and UK announced on June 2, 2025.
-
Outlook Therapeutics raises $13M in public offering of common stock and warrants
Offering of 9,285,714 shares and warrants to purchase 18,571,428 shares at combined price $1.40 per unit.
-
Outlook Therapeutics Q2 FY2025 net loss $46.4M; cash $7.6M; PDUFA Aug 27
Net loss $46.4M ($1.50/share) vs $114.3M ($8.01) YoY; adjusted net loss $12.5M ($0.40) vs $22.1M ($1.55).
-
Outlook Therapeutics awards $237,500 retention bonus to CFO/Interim CEO Kenyon
Cash retention bonus of $237,500 approved by Compensation Committee on April 9, 2025.
-
FDA accepts resubmission of OTLK's BLA for ONS-5010; PDUFA date set for August 27, 2025
FDA acknowledged receipt of resubmission of BLA for ONS-5010 (bevacizumab-vikg).
-
Outlook Therapeutics closes $33.1M convertible note, increases authorized shares to 260M
Issued $33.1M convertible note to Avondale Capital on March 13, 2025; proceeds used to repay $32.91M Streeterville note.
-
Outlook Therapeutics resubmits BLA for ONS-5010 to FDA
Resubmitted Biologics License Application for ONS-5010 to FDA on February 28, 2025.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.70 · Most common event regulatory